2026-06-06T01:36:18Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/453962026-02-13T00:45:26Zcom_10630_2254col_10630_37953

Development of Betalactam-Predictor: A clinical decision tool for delabeling low-risk Betalactam Allergy patients. Initial validation in penicillin allergy Labella, Marina Nuñez, Rafael Doña, Inmaculada Rodríguez de Guzmán, Julia Moreno, Esther Garvey, Lene Heise Laguna, Jose Julio Barbaud, Annick Bonnadona, Patrizia Boel, Jonas Bredtoft Mosbech, Holger Sfriso, Giovanna Castells, Mariana Phillips, Elizabeth Torres-Jaén, María Josefa Alergia a los medicamentos Penicilina Anafilaxia Antibiogramas Background: A label of betalactam (BL) allergy is estimated in around 10% of the population in their medical records. Second-line choices carry significant negative consequences, including reduced efficacy, effectiveness, and safety. This study aimed todevelop a new highly specific score constructed by selecting variables assisted by artificial intelligence to identify low-risk BL-allergic patients.Methods: In this study, derivation and validation of the BL-predictor score were performed on a retrospective cohort of 2207patients who underwent penicillin allergy testing at Málaga University Hospital (Spain). The development of the BL-predictorencompassed expert drafting and a two-step variable selection process consisting of univariate analysis and variable filtering,followed by stepwise logistic regression with resampling. To assess the efficiency, a multicentric retrospective external valida-tion was performed in 4261 patients from six populations: Salamanca and Madrid, Spain; Nashville, United States of America;Verona, Italy; Paris, France; and Copenhagen, Denmark.Results: The definitive questionnaire consisted of eight items and risk points were computed from the logistic regression modelas follows: +1 for reactions after first dose or in less than 1 h (ITEM-1), +2 for anaphylaxis (ITEM-2); +1 for previous reaction withthe culprit (ITEM-3); −1 for resolution in > 24 h (ITEM- 4); +2 for spontaneous resolution (ITEM-5); −2 for unknown symptoms 2026 journal article M. Labella, R. Nuñez, I. Doña, et al., “ Development of Betalactam-Predictor: A Clinical Decision Tool for Delabeling Low-Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy,” Allergy (2026): 1–13, https://doi.org/10.1111/all.70222. https://hdl.handle.net/10630/45396 https://doi.org/10.1111/all.70222 eng info:eu-repo/grantAgreement/EC/H2020/643309/EU http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 International Wiley